Full text

Turn on search term navigation

© 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

In particular, the Food and Drug Administration have approved abaloparatide, which is an analogue that is based on the N-terminal 1-34 sequence of human PTHrP, for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Several studies have demonstrated that both the N-terminal fragment and the PTH-unrelated C-terminal domain of PTHrP can enhance osteoblast proliferation and differentiation [1,2] and it can confer osteoinductive effects to implants in animal models of bone repair [3]. RA is characterized by an important alteration in bone homeostasis with an imbalance between bone resorption and formation [6]. [...]localized bone resorption and generalized bone loss are both associated to the progression of disease [7]. No studies have yet addressed if these peptides could control joint inflammatory conditions. [...]we have explored whether PTHrP (107-111) (osteostatin), which includes the -Thr-Arg-Ser-Ala-Trp- sequence of the PTHrP C terminal fragment, exerts inhibitory effects on inflammation and joint degradation in the collagen-induced arthritis (CIA).

Details

Title
Osteostatin Inhibits Collagen-Induced Arthritis by Regulation of Immune Activation, Pro-Inflammatory Cytokines, and Osteoclastogenesis
Author
Nácher-Juan, Josep; Terencio, María Carmen; Alcaraz, María José; Ferrándiz, María Luisa
Publication year
2019
Publication date
2019
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2333666731
Copyright
© 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.